SAN FRANCISCO, CA – December 12, 2023 – A landmark study, poised to redefine breast cancer screening paradigms, suggests that moving beyond universal annual mammograms towards a personalized, risk-adapted approach could significantly enhance safety and effectiveness for millions of women. Findings from the initial phase of the groundbreaking WISDOM study indicate that tailoring screening frequency to an individual’s unique risk profile can reduce the incidence of advanced cancer diagnoses while optimizing the allocation of crucial healthcare resources. This transformative research challenges long-held age-based screening protocols, advocating for a future where genetic, biological, and lifestyle factors dictate preventive care.
The comprehensive findings, based on data from 46,000 women across the United States, were published today in the prestigious medical journal JAMA and simultaneously presented at the highly anticipated San Antonio Breast Cancer Symposium. Coordinated by the University of California, San Francisco (UCSF), the WISDOM study ushers in a new era for breast cancer prevention, advocating for a paradigm shift from a one-size-fits-all model to a system meticulously crafted around individual risk evaluation.
"These findings should not only transform clinical guidelines for breast cancer screening but fundamentally alter clinical practice," asserted Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. Dr. Esserman emphasized the urgency of integrating personalized risk assessment into standard care, stating, "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."
Breast cancer remains an formidable adversary, standing as the most commonly diagnosed cancer among women in the United States, excluding non-melanoma skin cancers. For generations, screening guidelines operated under the assumption of a largely uniform risk across the female population, heavily relying on age as the primary determinant for initiating and continuing screening. This approach persisted despite a growing body of research unequivocally demonstrating that breast cancer risk is profoundly diverse, influenced by a complex interplay of inherited predispositions, lifestyle choices, and individual health histories. The WISDOM study directly confronts this historical uniformity, presenting compelling evidence for a more nuanced and patient-centric strategy.
The Paradigm Shift: A New Era in Breast Cancer Screening
For decades, the standard recommendation for breast cancer screening revolved around a relatively straightforward age-based schedule, most notably the encouragement of annual mammograms for women over a certain age, typically 40 or 50. This standardized approach, while credited with saving countless lives by detecting cancers earlier than they might otherwise have been found, has also faced scrutiny. Critics have pointed to potential downsides, including the risk of overdiagnosis (detecting cancers that would never have caused harm), overtreatment, and the psychological burden of false positives. Moreover, the inherent assumption of uniform risk overlooked the vast individual differences in susceptibility, leading to an inefficient allocation of resources – potentially over-screening low-risk individuals while under-screening those at higher risk who might benefit from more frequent or intensive monitoring.
The genesis of the WISDOM study was precisely to address these shortcomings and to pioneer a more intelligent, individualized approach. Launched in 2016, the study aimed to directly compare the efficacy and safety of traditional annual mammography against a dynamic, risk-based screening strategy. It sought to answer a fundamental question: Can we move beyond a simple age cutoff and instead leverage comprehensive personal data to optimize screening, making it both more effective in catching aggressive cancers and safer by reducing unnecessary interventions?
The study’s phased enrollment, beginning with women across various demographics and risk profiles, systematically built a robust dataset designed to provide definitive answers. UCSF’s role as the coordinating center underscored its leadership in innovative breast health research, bringing together a consortium of institutions dedicated to advancing the science of cancer prevention. The release of these initial phase results marks a pivotal moment, signaling a readiness to transition from theoretical discussions about personalized medicine to practical, evidence-based recommendations that could soon reshape national health policy.
Unpacking the WISDOM Study: Methodology and Revelations
The core innovation of the WISDOM study lies in its meticulously designed methodology, which directly pitted the conventional screening strategy against a personalized, risk-adapted one. Researchers employed a suite of well-validated risk models to group participants into four distinct categories. This comprehensive risk assessment went far beyond age alone, incorporating a sophisticated array of factors: chronological age, detailed genetic information, various lifestyle factors (such as diet, physical activity, and alcohol consumption), personal health history (including prior breast biopsies or benign conditions), and critical breast density measurements. The inclusion of breast density is particularly noteworthy, as dense breast tissue can both increase cancer risk and make mammographic detection more challenging.
The recommendations for screening frequency were then precisely tailored to each risk group:
- Lowest Risk Group (26% of participants): These women were advised to delay routine screening until age 50 or until a continuously updated algorithmic assessment indicated their risk level had naturally elevated to that of a typical 50-year-old woman. This group, representing a significant quarter of the study population, demonstrates the potential for reducing unnecessary early screenings without compromising safety.
- Average Risk Group (Approximately 62% of participants): The majority of women fell into this category, for whom biennial (every two years) mammograms were recommended. This diverges from the annual recommendation often given to average-risk women over 40 or 50, suggesting that less frequent screening is sufficient for a large segment of the population.
- Elevated Risk Group (8% of participants): For these women, annual mammograms were specifically advised. This group highlights the importance of identifying individuals who benefit from more frequent conventional screening.
- Highest Risk Group (2% of participants): This small but critically important group received the most intensive screening regimen: twice a year, alternating between mammography and magnetic resonance imaging (MRI), irrespective of their age. MRI is known for its higher sensitivity in detecting breast cancers, particularly in high-risk individuals and those with dense breasts.
A critical finding from the WISDOM study was the unequivocal demonstration that this personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This outcome is paramount, as it addresses a key concern often raised about modifying screening intervals – the fear of missing cancers that could progress to a more advanced stage between screenings. The study’s ability to maintain detection efficacy while individualizing frequency underscores the safety and scientific rigor of the risk-based model.
Furthermore, the study revealed a remarkable level of acceptance for the personalized approach. Among women who chose not to be randomized into one of the study arms but instead joined an observational group, a striking 89% opted for the risk-based screening strategy over traditional annual mammograms. This strong participant preference signals a readiness among women to embrace more informed, individualized health management.
Jeffrey A. Tice, MD, a UCSF professor of Medicine and co-author specializing in the development and evaluation of breast cancer risk assessment tools, emphasized the practical benefits of this re-allocation of resources. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice stated, highlighting the potential for optimized healthcare spending and improved patient outcomes.
Beyond Mammograms: The Power of Personalized Prevention and Genetics
The WISDOM study extended its innovative approach beyond just screening frequency, delving into personalized prevention strategies for women identified as having elevated or highest risk. These participants received tailored guidance designed to actively lower their chances of developing breast cancer. This support system included access to an advanced online decision-making tool specifically focused on breast health, providing them with evidence-based information and empowering them to make informed choices. Crucially, it also offered direct contact with a dedicated breast health specialist, ensuring expert guidance and addressing individual concerns. Recommendations spanned a spectrum of interventions, from lifestyle modifications such as improving diet and increasing physical activity – well-established factors in cancer prevention – to discussions about specific medications that can help reduce breast cancer risk in high-risk populations.
Perhaps one of the most profound and far-reaching implications of the WISDOM study centers on its expanded approach to genetic testing. Since its inception in 2016, the study has now enrolled over 80,000 women, intentionally including women as young as 30. This broader age inclusion aimed to identify individuals who might face an increased risk of aggressive early-onset cancers due to inherited genetic variants, even if they wouldn’t typically qualify for genetic screening under existing guidelines.
The study yielded a truly groundbreaking finding: a significant 30% of women who tested positive for a genetic variant linked to a higher breast cancer risk reported absolutely no family history of the disease. Under current clinical guidelines, which often require a strong family history or specific demographic criteria to qualify for genetic testing, many of these women would have remained unaware of their elevated risk. This discovery underscores a critical blind spot in contemporary screening protocols and highlights the immense potential of universal or expanded genetic testing to identify a previously hidden cohort of high-risk individuals.
Beyond well-known pathogenic variants such such as BRCA1 and BRCA2, the WISDOM study also explored the utility of smaller, more common DNA changes. These subtle genetic variations, when combined, can form a "polygenic risk score" (PRS). A PRS provides a nuanced statistical measure of an individual’s genetic predisposition to a disease, reflecting the cumulative effect of many common genetic variants, each contributing a small amount to overall risk. The integration of polygenic risk scores significantly improved the precision of risk predictions within the study, leading to 12% to 14% of participants being reassigned to a different, more accurate risk category. This refinement demonstrates the power of combining traditional risk factors with advanced genomic insights for a truly personalized assessment.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," noted Allison S. Fiscalini, MPH, co-author from UCSF and director of the Athena Breast Health Network and the WISDOM study. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." Her statement emphasizes the study’s pioneering role in democratizing access to crucial genetic information and integrating it into a holistic risk evaluation framework.
Expert Perspectives and Broader Implications
The collective voices of the WISDOM study’s lead researchers resonate with a clear call to action, emphasizing the profound implications of their findings for clinical practice and public health policy. Dr. Laura Esserman’s assertion that the results "should transform clinical guidelines" is not merely an academic pronouncement but a direct challenge to the status quo. It underscores the urgent need for medical societies, regulatory bodies, and healthcare providers to re-evaluate and update existing breast cancer screening recommendations to reflect this new evidence. The shift from age-based rules, which have governed screening for decades, to a system built around comprehensive individual risk evaluation represents a monumental change, requiring extensive education for both clinicians and patients.
Dr. Jeffrey Tice’s observation regarding the efficiency of "shifting resources from lower-risk women to higher-risk women" highlights a critical aspect often overlooked in discussions about healthcare delivery: the economic and practical implications. In an era of escalating healthcare costs and finite resources, the ability to optimize screening by directing intensive interventions to those who need them most can lead to more cost-effective care without sacrificing—and indeed, improving—outcomes. This model could alleviate the burden of unnecessary screenings on lower-risk individuals, freeing up resources that can then be strategically deployed to offer more frequent and advanced imaging, such as MRI, to those at significantly higher risk. This not only enhances patient safety by reducing radiation exposure and false positives for the low-risk group but also improves the chances of early detection for the high-risk group.
Allison Fiscalini’s perspective further reinforces the potential for a "real impact on improving the safety and effectiveness of screening and prevention." Her emphasis on the integration of genetic testing, particularly the revelation that a substantial proportion of women with high-risk genetic variants lack a family history, points to a paradigm shift in how we identify at-risk individuals. Implementing universal or broader genetic testing could fundamentally alter risk assessment, allowing for proactive intervention and prevention strategies for a previously unidentified segment of the population.
The broader implications of the WISDOM study extend beyond clinical guidelines. For patients, it offers the promise of more personalized, less anxiety-inducing, and ultimately more effective care. For healthcare providers, it necessitates a deeper understanding of risk assessment tools, genetic counseling, and the nuances of tailored screening protocols. For public health, it presents an opportunity to refine population-level screening programs, potentially leading to a reduction in advanced-stage breast cancer diagnoses and a more efficient healthcare system. However, the widespread adoption of risk-based screening is not without its challenges. Ensuring equitable access to comprehensive risk assessment, including genetic testing and breast density evaluation, will be paramount, particularly for underserved populations. The infrastructure for genetic counseling, the training of healthcare professionals, and the integration of complex risk algorithms into electronic health records will all require significant investment and coordination.
The Road Ahead: WISDOM 2.0 and the Future of Screening
The journey toward fully optimized, personalized breast cancer screening continues. Researchers are not resting on the laurels of these initial findings but are actively engaged in refining risk assessment through the ongoing WISDOM 2.0 study, which is currently enrolling participants. The ambitious goal of WISDOM 2.0 is to further enhance the precision of risk identification, particularly focusing on better identifying women who face a higher likelihood of developing aggressive breast cancers. By continuously refining the models and incorporating new data, the study aims to provide these women with screening and prevention strategies that are not only tailored to their immediate risk but also aligned with their long-term health needs, promising a future of increasingly precise and proactive breast health management.
The WISDOM study represents a pivotal moment in the fight against breast cancer. By meticulously demonstrating the superior efficacy and safety of a personalized, risk-adapted screening approach over a generalized one, it lays the groundwork for a profound transformation in clinical practice. The integration of genetic insights, comprehensive risk modeling, and tailored prevention strategies offers a powerful vision for the future—a future where breast cancer screening is not just routine, but truly intelligent, precise, and profoundly personalized.
Co-Authors: From UCSF, authors include Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Other investigators are at UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.
Funding: Study support included the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation. Please see the full paper for other funding sources.
Conflicts of Interest: Dr. Esserman is a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource. Please see the full paper for disclosures of other investigators.
About the Author
